by Stefan Ravello | May 11, 2026 | Oncology, PARP-Combination Therapy, Prostate Cancer
Prostate cancer is the most common solid cancer in men worldwide. Most men are diagnosed as having localized disease because of the widespread use of prostate-specific antigen screening. Men diagnosed as having clinically localized prostate cancer have multiple...
by Stefan Ravello | May 11, 2026 | Breast Cancer, Oncology
Early-stage hormone receptor-positive, HER2-negative (HR+/HER2−) breast cancer is the most common breast cancer subtype, accounting for roughly two-thirds to three-quarters of all new breast cancer cases in the United States (U.S.). Endocrine therapy (ET) has long...
by Stefan Ravello | May 11, 2026 | Hematology-Oncology, Multiple Myeloma
Multiple myeloma (MM) is a malignant plasma cell disorder and the second most common blood cancer in the United States (U.S.) Survival has improved markedly with modern therapies – the 5-year survival rate has more than doubled in recent decades – yet myeloma remains...
by Stefan Ravello | Feb 11, 2026 | Neurology
The recent development and approval of blood-based biomarker tests (BBMs) for detecting neuropathologic changes associated with Alzheimer’s disease (AD) can enhance the care of patients by facilitating earlier diagnosis in both primary care and specialty settings....
by Stefan Ravello | Feb 11, 2026 | Psychiatry
In the United States (U.S.), major depressive disorder (MDD) is a prevalent and debilitating illness with a high burden of disease. Effective management of depression is therefore critical, yet achieving and sustaining remission remains challenging in practice. While...
